BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Giannetta E, La Salvia A, Rizza L, Muscogiuri G, Campione S, Pozza C, Colao AAL, Faggiano A. Are Markers of Systemic Inflammatory Response Useful in the Management of Patients With Neuroendocrine Neoplasms? Front Endocrinol (Lausanne) 2021;12:672499. [PMID: 34367064 DOI: 10.3389/fendo.2021.672499] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Budek M, Nuszkiewicz J, Piórkowska A, Czuczejko J, Szewczyk-Golec K. Inflammation Related to Obesity in the Etiopathogenesis of Gastroenteropancreatic Neuroendocrine Neoplasms. Biomedicines 2022;10:2660. [PMID: 36289922 DOI: 10.3390/biomedicines10102660] [Reference Citation Analysis]
2 Liu M, Hu W, Zhang Y, Zhang N, Chen L, Lin Y, Wang Y, Luo Y, Guo Y, Chen M, Chen J. Clinical implications of immune checkpoint markers and immune infiltrates in patients with thymic neuroendocrine neoplasms. Front Oncol 2022;12:917743. [DOI: 10.3389/fonc.2022.917743] [Reference Citation Analysis]
3 Rahman MM, Behl T, Islam MR, Alam MN, Islam MM, Albarrati A, Albratty M, Meraya AM, Bungau SG. Emerging Management Approach for the Adverse Events of Immunotherapy of Cancer. Molecules 2022;27:3798. [PMID: 35744922 DOI: 10.3390/molecules27123798] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
4 Olsen TA, Zhuang TZ, Caulfield S, Martini DJ, Brown JT, Carthon BC, Kucuk O, Harris W, Bilen MA, Nazha B. Advances in Knowledge and Management of Immune-Related Adverse Events in Cancer Immunotherapy. Front Endocrinol 2022;13:779915. [DOI: 10.3389/fendo.2022.779915] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]